Diversified Health Systems Limited (Registered Number 300462)

Annual Report and Financial Statements

For the year ended 31st December 2006

Registered office address^{*} 980 Great West Road Brentford Middlesex TW8 9GS





7 16/04/2007 COMPANIES HOUSE

274

Annual Report and Financial Statements

For the year ended 31st December 2006

	Pages
Directors' Report	1-2
Independent Auditors' Report	3
Profit and Loss Account	4
Balance Sheet	5
Notes to the Financial Statements	6-9

Directors' Report for the year ended 31st December 2006

The Directors submit their report and the audited financial statements for the year ended 31st December 2006

Principal activities

The principal activity of the Company is the payment and receipt of interest. The Directors do not envisage any change to the nature of the business in the foreseeable future.

Review of business

The Company made a loss on ordinary activities after taxation of £524,000 (2005 - loss of £495,000). The Directors are of the opinion that the current level of activity and the year end financial position are sustainable, and the company remains a going concern

The retained loss for the year of £524,000 will be transferred from reserves (2005 - retained loss for the year of £495,000 transferred from reserves)

Results and dividends

The Company's results for the financial year are shown in the profit and loss account on page 4

No dividend is proposed to the holders of Ordinary Shares in respect of the year ended 31st December 2006 (2005 - £nil)

Directors and their interests

The Directors of the Company who served during the year are as follows

Glaxo Group Limited

Edinburgh Pharmaceutical Industries Limited

No Director had, during the year or at the end of the year, any material interest in any contract of significance to the Company's business except where such an interest may arise in the ordinary course of business

Save as disclosed, no arrangements to which the Company was a party existed at the end of the year, or at any time during the year, which would enable the Directors to acquire benefits through the acquisition of shares, or debentures of the Company, or any body corporate within the GlaxoSmithKline Group (the Group)

At 31st December 2006 none of the Directors have beneficial interests in the shares of any other Group company, except where such a beneficial interest may arise in the ordinary course of business

Directors' indemnity

Each of the Directors benefits from an indemnity given by the Company under its articles of association. This indemnity is in respect of liabilities incurred by the Director in the execution and discharge of its duties.

Directors' Report for the year ended 31st December 2006

Statement of directors' responsibilities

Company law requires the Directors to prepare financial statements for each financial year that give a true and fair view of the state of affairs of the Company and of the profit or loss for that year

In preparing the financial statements the Directors are required to

- · Select suitable accounting policies and then apply them consistently
- Make judgements and estimates that are reasonable and prudent
- State whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements

The Directors confirm that they have complied with the above requirements in preparing the financial statements

The Directors are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the Company and to enable them to ensure that the financial statements comply with the Companies Act 1985. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

As far as the Directors are aware, there is no relevant audit information of which the Company's auditors are unaware, and the Directors have taken all the steps that ought to have been taken to make themselves aware of any relevant audit information and to establish that the Company's auditors are aware of that information

After making enquiries, the Directors have a reasonable expectation that the Company has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the accounts

Auditors

Elective resolutions to dispense with holding Annual General Meetings, the laying of accounts before the Company in general meetings and the appointment of Auditors annually are currently in force. The Auditors, PricewaterhouseCoopers LLP, will therefore be deemed to have been reappointed at the end of the period of 28 days beginning with the day on which copies of this Report and Accounts are sent to members unless a resolution is passed under Section 393 of the Companies Act to the effect that their reappointment be brought to an end

By order of the Board

P Williamson

For and on behalf of Edinburgh Pharmaceutical Industries Limited

Company Secretary

26 March 2007

Independent Auditors' Report to the shareholders of Diversified Health Systems Limited

We have audited the financial statements of Diversified Health Systems Limited for the year ended 31st December 2006 which comprise the Profit and Loss Account, the Balance Sheet, and the related notes These financial statements have been prepared under the accounting policies set out therein

Respective responsibilities of directors and auditors

The directors' responsibilities for preparing the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) are set out in the Statement of Directors' Responsibilities

Our responsibility is to audit the financial statements in accordance with relevant legal and regulatory requirements and International Standards on Auditing (UK and Ireland). This report, including the opinion, has been prepared for and only for the Company's members as a body in accordance with Section 235 of the Companies Act 1985 and for no other purpose. We do not, in giving this opinion, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

We report to you our opinion as to whether the financial statements give a true and fair view and are properly prepared in accordance with the Companies Act 1985. We also report to you whether in our opinion the information given in the Directors' Report is consistent with the financial statements.

We also report to you if, in our opinion, the Company has not kept proper accounting records, if we have not received all the information and explanations we require for our audit, or if information specified by law regarding directors' remuneration and other transactions is not disclosed

We read the Directors' Report and consider the implications for our report if we become aware of any apparent misstatements within it

Basis of audit opinion

We conducted our audit in accordance with International Standards on Auditing (UK and Ireland) issued by the Auditing Practices Board. An audit includes examination, on a test basis of evidence relevant to the amounts and disclosures in the financial statements. It also includes an assessment of the significant estimates and judgments made by the directors in the preparation of the financial statements, and of whether the accounting policies are appropriate to the Company's circumstances, consistently applied and adequately disclosed.

We planned and performed our audit so as to obtain all the information and explanations which we considered necessary in order to provide us with sufficient evidence to give reasonable assurance that the financial statements are free from material misstatement, whether caused by fraud or other irregularity or error. In forming our opinion we also evaluated the overall adequacy of the presentation of information in the financial statements.

Opinion

In our opinion

- the financial statements give a true and fair view, in accordance with United Kingdom Generally
 Accepted Accounting Practice, of the state of the Company's affairs at 31st December 2006 and of
 its loss for the year then ended,
- the financial statements have been properly prepared in accordance with the Companies Act 1985, and
- . the information given in the Directors' Report is consistent with the financial statements

Priewaterhous Cooper us

PricewaterhouseCoopers LLP
Chartered Accountants and Registered Auditors
26 March 2007

Profit and Loss Account For the Year Ended 31st December 2006

		2006	2005
-	Notes	£'000	£'000
Administrative expenses		(6)	(6)
Other operating income		-	3
Operating loss	2	(6)	(3)
Interest payable	3	(742)	(702)
Loss on ordinary activities before taxation		(748)	(705)
Taxation	4	224	210
Loss on ordinary activities after taxation		(524)	(495)
Retained loss	8	(524)	(495)

The results disclosed above relate entirely to continuing operations

There is no difference between the loss on ordinary activities before taxation and the retained loss stated above and their historical cost equivalents

The company had no recognised gains or losses during the year other than those reflected in the above profit and loss account

The notes on pages 6 to 9 form part of these statements

Balance Sheet As at 31st December 2006

		2006	2005
	Notes	£'000	£'000
Debtors	5	857	633
Cash at bank	-	-	-
Current assets		857	633
Creditors: amounts due within one year	6	(15,257)	(14,509)
Net current liabilities		(14,400)	(13,876)
Net liabilities		(14,400)	(13,876)
Capital and reserves			
Called up share capital	7	15,000	15,000
Profit and loss account	8	(29,400)	(28,876)
Equity shareholder's funds	9	(14,400)	(13,876)

The accounts on pages 4 to 9 were approved by the Board of Directors on 26 March 2007 and were signed on its behalf by

A Grist

For and on behalf of Edinburgh Pharmaceutical Industries Limited - Director

The notes on pages 6 to 9 form part of these statements

Notes to the Financial Statements for the year ended 31st December 2006

1 Accounting policies

The principal accounting policies adopted in the preparation of these financial statements are set out below

(a) Basis of accounting

These financial statements have been prepared using the historical cost convention, and have been drawn up in accordance with UK generally accepted accounting principles and with UK accounting presentation

(b) Foreign currency transactions

Foreign currency transactions are booked in local currency at the exchange rate ruling on the date of the transaction, or at the forward rate if hedged by a forward exchange contract. Foreign currency assets and liabilities are translated into local currency at rates of exchange ruling at the balance sheet date, or at the forward rate. Exchange differences are included in operating loss.

(c) Taxation

The Company accounts for taxation which is deferred or accelerated by reason of timing differences which have originated but not reversed by the balance sheet date. Deferred tax assets are only recognised to the extent that they are considered recoverable against future taxable profits.

Current tax is provided at the amounts expected to be paid applying tax rates that have been enacted or substantially enacted by the balance sheet date

Deferred tax is measured at the average tax rates that are expected to apply in the periods in which the timing differences are expected to reverse. Deferred tax liabilities and assets are not discounted

2 Operating loss

	2006	2005
	£'000	£'000
The following items have been charged/(credited) in operating loss		
Exchange gains on foreign currency transactions	-	(3)
Management charge	6	6

GlaxoSmithKline Services Unlimited provides various services and facilities to the Company including finance and administrative services for which a management fee is charged. Included in this charge is Auditor Remuneration of £3,000 (2005 - £2,500)

3 Interest payable

	2006	2005
	£'000_	£'000
Interest payable		
On loans with group undertakings	(742)	(702)

Notes to the Financial Statements for the year ended 31st December 2006

4	Taxation				
				2006	2005
	Taxation charge/(credit) based on profits for the period	d		£'000	£'000
	UK corporation tax at 30% (2005 - 30%)			(222)	(210)
	Prior year adjustment to current tax			(2)	(210)
					(240)
				(224)	(210)
				2006	2005
	Reconciliation of the taxation charge			£'000	£'000
	Tax on ordinary losses at UK standard tax rate		·	(224)	(212)
	Expenses not deductible			223	211
	Prior year adjustments			(2)	-
	Amount receivable from group companies			(223)	(211)
	Other permanent differences			2	2
	Current tax charge for the period			(224)	(210)
_	D 14				
5	Debtors			2006	2005
				£'000	£'000
			-	2 000	2000
	Amounts due within one year				
	Amounts owed by group undertakings			857	633
				857	633
_					
6	Creditors			2006	2005
				£'000	£'000
	-	-	-	£ 000	£ 000
	Amounts due within one year				
	Amounts owed to group undertakings			15,256	14,508
	Taxation			1	1
				15,257	14,509
					
7	Called up share capital - equity interests	2006	2005	2006	2005
		2006 Number of	2005 Number of	2006	2005
		shares	shares	£'000	£'000
	Authorised				
	Ordinary Shares of £1 each	15,000,300	15,000,300	15,000	15,000
	Ordinary Shares of £1 each	13,000,300	10,000,000	13,000	15,500
	Issued and fully paid				
	Ordinary Shares of £1 each	15,000,300	15,000,300	15,000	15,000

Notes to the Financial Statements for the year ended 31st December 2006

8 Reserves - equity interests

			Profit & Loss account
			£'000
	At 1st January 2006 Loss for the financial year		(28,876) (524)
	At 31st December 2006		(29,400)
9	Reconciliation of movement in shareholders' funds		
		2006 £'000	2005 £'000
	Loss for the financial year	(524)	(495)
	Opening shareholder's funds	(13,876)	(13,381)
	Closing shareholder's funds – equity interests	(14,400)	(13,876)

10 Contingent liabilities

The Company, together with fellow group undertakings has entered into a group banking arrangement with the Company's principal bankers. The Bank holds the right to pay and apply funds from any account of the Company to settle any indebtedness to the Bank of any other party to this agreement. The Company's maximum potential liability is limited to the amount held on its account with the Bank. No loss is expected to accrue to the Company from the agreement.

11 Employees

The Company has no employees as all personnel are employed by other Group companies

12 Directors' remuneration

The Corporate Directors received no remuneration in respect of their services to the Company (2005 - £nil)

13 Cash flow statement

A cash flow statement has been included in the consolidated financial statements of GlaxoSmithKline plc, the ultimate parent undertaking. As a wholly owned subsidiary of the ultimate parent undertaking, advantage has been taken of the exemption afforded by FRS 1 'Cash Flow Statements' (Revised 1996) not to prepare a cash flow statement

Notes to the Financial Statements for the year ended 31st December 2006

14 Ultimate parent undertaking

GlaxoSmithKline plc, a company registered in England and Wales, is the Company's ultimate parent undertaking. The largest and smallest group of undertakings for which group financial statements are prepared and which include the results of the Company, are the consolidated financial statements of GlaxoSmithKline plc. Copies of the consolidated financial statements can be obtained from The Company Secretary, GlaxoSmithKline plc, 980 Great West Road, Brentford, Middlesex TW8 9GS. The immediate parent undertaking is SmithKline Beecham plc.

15 Related party transactions

As a wholly owned subsidiary of the ultimate parent company, GlaxoSmithKline plc, advantage has been taken of the exemption afforded by FRS 8 'Related Party Disclosures' not to disclose any related party transactions within the Group There are no other related party transactions